January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

South Ko­re­an bio­phar­ma con­tract man­u­fac­tur­er Cell­tri­on is con­sid­er­ing ac­quir­ing US man­u­fac­tur­ing sites to mit­i­gate Pres­i­dent Don­ald Trump’s po ...

Seoul, Jan 31 (IANS): Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA ® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...

Tocilizumab-anoh is the seventh biosimilar by Celltrion to receive FDA approval, enhancing their treatment portfolio. Avtozma, the third biosimilar to Actemra, has received FDA approval for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA.

(MENAFN- IANS) Seoul, Jan 31 (IANS) Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US ...

“Introducing both IV and SC formulations of AVTOZMA provides flexibility and a wider range of treatment options,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “This approval ...